Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, first-in-class PD-1/VEGF bispecific ...
Patients with relapsed/refractory CLL who received zanubrutinib achieved significantly superior PFS compared with ibrutinib. The prescribing information for Brukinsa ® (zanubrutinib) has been updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback